A team of Canadian researchers has been formed to develop new genomics tools they hope will lead to the breeding of pigs resistant to multiple swine diseases.
The march of IBM's Watson into biopharma R&D is continuing apace. Icon and Teva are the latest companies to ink deals to access the computer system, giving them new ways to match patients to clinical trials and create disease models.
Johns Hopkins University, Cedars-Sinai and Massachusetts General Hospital have raised $20 million to fuel a research initiative to understand the cause of amyotrophic lateral sclerosis.
Melinta Therapeutics CEO Mary Szela has left the company in the middle of a late-stage program for its lead antibiotic, a move that comes just months after the biotech raised $67 million in equity financing.
Eli Lilly, blueprinting an R&D hub outside Boston, is expanding the square footage of its new outpost, snatching up more of the increasingly costly lab space in biotech's most in-demand neighborhood.
Exosome Diagnostics is trotting out promising data for its lung cancer liquid biopsy test, a week after reeling in new funds to support development of its liquid biopsy technology and build out its portfolio.
Engineering professor Beth Kolko is on a mission to sell low-cost devices. She's dismayed at the current landscape, which favors high-cost devices because cheaper alternatives can't support the sales forces needed to sell them, according to one industry exec.
Up to now, San Diego-based AnaptysBio has raised close to $49 million in cash directly from collaborators looking to the antibody shop to use their technology to create some promising new programs--slightly more than its cumulative burn rate over the years. Now, it's filed papers with the SEC for an $86 million IPO, looking to join the queue of biotechs out to test the marketplace in the wake of some severe turbulence.
Germany's CureVac has launched a subsidiary in the biotech hotbed of Cambridge, MA, hoping to accelerate the development of its messenger RNA therapies on the heels of a major investment from the Bill and Melinda Gates Foundation.
Royal Philips has started its first center to back digital healthcare innovation at High Tech Campus Eindhoven in the Netherlands. The "co-creation center" is intended to be the first of several global R&D sites in which the conglomerate supports the development of healthcare solutions focused on patient self-management and continuity of care.